AmerisourceBergen Completes Acquisition of PharmaLex

Rhea-AI Summary

AmerisourceBergen Corporation (NYSE: ABC) has successfully completed its acquisition of PharmaLex Holding GmbH, enhancing its growth strategy. This acquisition strengthens AmerisourceBergen's leadership in specialty services and expands its global pharmaceutical manufacturer capabilities. The addition of PharmaLex's regulatory affairs, development consulting, pharmacovigilance, and compliance services positions AmerisourceBergen as a leading partner for biopharmaceutical companies throughout the drug development and commercialization process.

Positive

• Strengthened position as a leader in specialty services.
• Expanded capabilities in regulatory affairs and compliance services.
• Enhanced global pharmaceutical manufacturer services.

Negative

• None.

Acquisition advances role as a partner of choice for biopharmaceutical companies by enhancing global portfolio of specialty services

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of its acquisition of PharmaLex Holding GmbH.

The acquisition of PharmaLex enhances AmerisourceBergen’s growth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services capabilities. PharmaLex’s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance services expand AmerisourceBergen’s role as partner of choice for biopharmaceutical partners across the pharmaceutical development and commercialization journey.

About AmerisourceBergen

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our approximately 44,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221231005019/en/

Investors:

Bennett S. Murphy

610-727-3693

bmurphy@amerisourcebergen.com

Media:

Lauren Esposito

215-460-6981

lesposito@amerisourcebergen.com

Source: AmerisourceBergen Corporation

FAQ

What is the significance of AmerisourceBergen's acquisition of PharmaLex?

The acquisition enhances AmerisourceBergen's leadership in specialty services and expands their global capabilities in pharmaceutical manufacturer services.

How will the acquisition of PharmaLex affect AmerisourceBergen's stock (ABC)?

The acquisition is expected to positively impact AmerisourceBergen's growth strategy and enhance its role as a partner for biopharmaceutical companies.

When was the acquisition of PharmaLex by AmerisourceBergen announced?

The acquisition was announced on December 31, 2022.

What are the key services added to AmerisourceBergen through the PharmaLex acquisition?

The acquisition adds regulatory affairs, development consulting, pharmacovigilance, and quality management services.